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OBJECTIVE: Transdermal (TD) opioids are commonly used to
treat various chronic pain conditions. A large register-based
study has shown coherence between an increased fracture risk in
elderly patients with osteoporosis and prior opioid administra-
tion due to side effects impacting on the central nervous system
(e.g. dizziness). Thus, the objective is to investigate the cost-
effectiveness of TD opioids in elderly patients with chronic pain
in Germany, considering the long-term implications of opioid-
related fractures. METHODS: A Markov model was developed
to assess the consequences of hip, spine and forearm fractures
related to the prior application of TD buprenorphine or generic
TD fentanyl for a maximum of 89 days in patients with chronic
pain. Mean costs per patient as well as incremental costs per life
year gained and per quality-adjusted life year (QALY) gained
were evaluated from both the perspective of the German statu-
tory health insurance (SHI) and the German social security (GSS)
over a six year time horizon. RESULTS: The Markov simulation
predicts both a slightly better survival and higher utility score for
TD buprenorphine compared to TD fentanyl (about 5.19 years
with almost 4.21 QALYs versus nearly 5.17 years with about
4.19 QALYs). From the SHI perspective, the mean costs per
patient after six years amount to €683.96 under TD buprenor-
phine and €853.55 under TD fentanyl, respectively. From the
GSS perspective, the mean costs per patient after six years were
€808.29 with TD buprenorphine compared to €1155.90 with TD
fentanyl. The model was robust regarding probabilistic varia-
tions of all parameters in the sensitivity analyses (50,000 runs,
sampling 500 times per run). CONCLUSION: Focusing on
fractures related to the prior administration of TD opioids,
buprenorphine represents a dominant treatment option in the
management of patients suffering from chronic pain compared to
fentanyl from both the SHI and GSS perspective in Germany.
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OBJECTIVE: Dasatinib is indicated for the treatment of adults
with CML with resistance or intolerance to Imatinib therapy.
This study assessed the cost and cost-effectiveness of using Dasa-
tinib when compared with Imatinib for the treatment of indi-
viduals with CML in México. METHODS: A cost effectiveness
life-time Markov model was used to calculate the incremental
cost per life year gained (LYG) of the compared therapies. The
model follows patients with CML considering the different
phases of the disease, adverse events and the resource utilization
so generated. There are three different scenarios depending on
the phase (chronic, accelerated or blast) patients are started in the
model. The Delphi Panel technique was used to provide estimates
of the use of health care resources by CML patients within the
setting of the Mexican Social Security Institute (IMSS). Transi-
tion probabilities and relative risks were estimated from pub-
lished international literature. The base case analysis was from a
health care perspective. Costs of drugs and other health care
treatments were obtained from IMSS published information and
were discounted at 3%. A one-way sensitivity analysis was per-
formed. RESULTS: The economic evaluation showed that in the
chronic phase Dasatinib was more effective (LYG difference of
.71) and less costly (-USD$35,368) than Imatinib therapy. In the
accelerated phase the incremental cost effectiveness ratio (ICER)
per life year gained with Dasatinib was USD$36,366 when com-
pared with Imatinib. Finally, in the blast phase the model showed
for Dasatinib costs of USD$154,900 and effectiveness of 2.13
LYG and for Imatinib costs of USD$41,927 and 1.58 LYG. These
ﬁndings were robust to deterministic sensitivity analysis. CON-
CLUSION: In México, Dasatinib is a cost effective therapy for
the management of Imatinib resistant patients with CML in the
chronic phase. In the accelerated and blast phases Dasatinib
generates incremental costs because treatment continues indeﬁ-
nitely due to prolonged survival.
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OBJECTIVE: Acute pain associated with injuries (i.e., sprains,
strains, contusions, and low back pain) is treated with non-
steroidal anti-inﬂammatory drugs (NSAIDS) or topical anesthet-
ics. These agents vary in effectiveness, may have gastrointestinal
and cardio-renal side effects, and possibly interact with other
systemic medications. Diclofenac epolamine topical patch
(DETP) is a treatment option with minimal systemic absorption,
low risk of adverse drug-drug interactions, and local anti-
inﬂammatory properties. This analysis was designed to deter-
mine the cost-effectiveness of DETP versus lidocaine patch in the
treatment of acute pain. METHODS: A decision analysis meth-
odology was utilized to develop a model which served as an
analytical decision support tool, where the expected values of the
competing agents were calculated and compared. Published data
was used to populate the efﬁcacy and adverse event probabilities
for treatment with DETP and lidocaine patch. We adjusted costs
to 2007 dollars and used each drug’s average daily cost (ADC),
as well as overall medical care costs associated with various
outcomes. The ADC in this analysis for DETP and lidocaine
patch was $7.65 and $14.08, respectively. RESULTS: The total
drug costs for a two-week duration of DETP and lidocaine patch
were $107.10 and $197.12, respectively. The total health care
costs (ofﬁce visits and additional medical services) for therapy
with DETP and lidocaine patch were $290.22 and $380.53,
respectively. The 2-week course of therapy yielded a resultant
cost-effectiveness of $401.42 for DETP and $556.34 for
lidocaine patch. When the treatment timeframe was evaluated
for 30 days, the cost-effectiveness for DETP and lidocaine patch
was $551.31 and $885.69, respectively. CONCLUSION:
Although further validation is warranted and future studies may
need to be expanded to include other agents, preliminary results
demonstrate that the DETP may represent a cost-effective alter-
native to lidocaine patch in the management of acute pain.
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